目的对《中国医院制剂规范》中人工泪滴眼液处方和制备工艺进行改进，并观察对比改进前后的疗效。
Objective To evaluate the clinical, effects of modified artificial tears gutta depended on the "pharmaceutics regulates of hospitals in China".
美国食品与药物管理局尚未对银杏制剂和其它保健品进行规范化管理，商标不同，药品的效力和纯度也不一样。
Since the Food and Drug Administration do not regulate ginkgo and other supplements, potency and purity vary from brand to brand.
应用木霉制剂防治药用植物病害中药材的规范化种植提供了技术保证。
Using the preparation to control medicinal plant diseases provides a technical safeguard for the good agricultural practice of medicinal plants.
应用推荐